Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.

Trial Details

NCT ID
NCT06005324
Phase
PHASE1
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Paclitaxel
  • Carboplatin
  • Cetuximab
  • Standard Dose Radiation
  • Low Dose Radiation
  • Cisplatin
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Patients must have pathologically confirmed locally advanced, non-metastatic, human papillomavirus (HPV) negative head and neck squamous cell carci…
  • Stage III or IV disease based on American Joint Committee on Cancer (AJCC) staging 8th edition.
  • If a primary oropharyngeal squamous cell carcinoma is diagnosed, HPV must be ruled out by immunohistochemistry.
  • Availability of ≥10 unstained 5 micron slides. Patients who cannot fulfill this requirement will need to undergo a new biopsy prior to enrollment o…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →